SPONSORED BY AstraZeneca

ARC
ADVANCING RENAL CARE
SUMMIT | 1ST EDITION

ENDORSED BY

EHES | EMANI | OSNT | SEHA KIDNEY CARE

7–8 November 2026

Jumeirah Emirates Towers, Dubai

Featuring

ULTOMIRIS IgAN LAUNCH EVENT IN UAE

Day 1 — Saturday 7 November 2026

Opening: Advances in the Management of Rare Disease

TIME	TOPIC	SPEAKER
17:45–18:20	Registration & Foyer Activation Explore aHUS Journey	
18:20–18:40	AZ in Nephrology Landscape	AZ
18:40–18:45	Chairman's Opening	Dr. Ayman Al Madani

Part 1: From Suspicion to Sustained Control — Building an Integrated MDT Approach to aHUS – Complement-Mediated TMA

Session 1 — Chairman: Dr. Issa Al Salmi (Oman)

TIME	TOPIC	SPEAKER
18:45–18:55	Welcome & Meeting Objectives: Why Time Matters in aHUS	Dr. Issa Al Salmi
18:55–19:05	aHUS Pathophysiology, Disease Burden & the Case for Rapid Identification Complement dysregulation • Clinical, humanistic, and economic burden Consequences of diagnostic delay & Disease Epidemiology	Dr. Tofol Al Noshmi
19:05–19:20	Diagnosing aHUS: A Disease of Exclusion TMA triad recognition • Role of ADAMTS-13 • PLASMIC score application • Differentiating aHUS from TTP and secondary TMAs	Prof. David Kavanagh (UK)
19:20–19:35	Pre-Transplant aHUS Screening: Rediscovering the Missed Patients Importance of systematic screening of ESRD patients on the transplant list to detect previously undiagnosed aHUS.	Dr. Zeyana Al Hadhrami Dr. Faisal Basonbul
19:35–19:55	Panel 1: Building the MDT Lens — Who Detects aHUS First? Roles and responsibilities of Nephrology • ICU • Internal Medicine • Hematology – Pathology in early detection, referral, and avoiding misdiagnosis.	Prof. David Kavanagh Dr. Mohammed Amari Dr. Lool Eid Dr. Ali Eldali Dr. Mahamad Tarik Bakri Dr. Mohamed Hassan Christine Mavilia (UK)
19:55–20:15	Role of Terminal Complement Inhibitor in the Management of aHUS – a Complement-Mediated TMA	Prof. David Kavanagh
20:15–20:20	Break	

Session 2 — Chairman: Dr. Issa Al Salmi (Oman)

Panelists: *Dr. Ahmed Al Qafaf (Kuwait), Dr. Loai Eid, Dr. Ayman Al Madani, Dr. Mohammed Amari, Dr. Hormaz Dastoor, Prof. David Kavanagh, Dr. Tofol Al Noshmi, Dr. Mahamad Tarik Bakri, Christine Mavilia, Amar Lal.*

TIME	TOPIC	SPEAKER
20:20–20:40	Trigger Spotlight 1: Infection- Associated TMA 2 real clinical cases followed by panel reflection and data discussion on infection as an aHUS trigger.	Dr. Loai Eid (UAE)
20:40–21:00	Trigger Spotlight 2: Malignant Hypertension (MHT) 2 real clinical cases followed by panel reflection and data on MHT-triggered aHUS.	Dr. Tofol Al Noshmi (Saudi Arabia)
21:00–21:20	Trigger Spotlight 3: Kidney Transplantation 1–2 real clinical cases followed by panel reflection and data on transplant-associated aHUS.	Dr. Zeyana Al Hadhrami
21:20–21:30	Trigger Spotlight 4: Postpartum 1 real clinical case followed by panel reflection and data on postpartum aHUS.	Dr. Sadeq Al Lawati
21:30–21:40	Closing, Consensus & Q&A Key takeaways - MDT call to action - Building the integrated protocol Suspect • Diagnose • Refer • Treat	Dr. Ayman Al Madani Dr. Issa Al Salmi
21:40-22:40	Dinner	

Parallel Workshop

aHUS HST/SKC Workshop — Chairman: Dr. Ayman Al Madani
Moderators: Dr. Dastoor Hormaz & Dr. Dana Kidder

TIME	TOPIC	SPEAKER
15:00–15:30	aHUS Key Diagnostic Criteria that need to be implemented on a system level to optimize the management of aHUS	Prof. David Kavanagh Dr. Hormaz Dastoor
15:30–16:30	**Workshop** **Identification:** Define who is being missed, where, and why. Standardize clinical and laboratory triggers for suspected TMA / aHUS. Focus on high-risk entry points: ER, ICU, and transplant. Identify leakage points in the current patient journey. **Referral & MDT Pathway:** Create a clear escalation architecture across specialties. Build agreed pathway between nephrology, haematology, transplant, ICU, and pathology/lab medicine. Define who refers, who is contacted, when, and on what basis. Establish a rapid MDT review model for suspected complement-mediated TMA. **System Integration:** Embed the pathway into care delivery. EMR prompts / flag logic. Standardized order sets / checklists. Operational governance and measurable KPIs. Case capture for quality improvement and future institutional learning.	**Nephrology:** Dr. Hormaz Dastoor Dr. Dana Kidder, Dr. Emad Khater **Transplant:** Dr. Mohamed Yahya Al Seiari Dr. Faisal Basonbul **ER/ICU:** Dr. Mohammed Amari Dr. Ali Al Eldali **Pathology/Lab Medicine:** Dr. Carlo Kaabar Dr. Stefan Weber **IT/EMR/Digital:** Ammar Bin Mujeeb **Quality/Administration:** Nishad Olpen Gostman Christine Mavilia Nurse Consultant (aHUS) **Internal medicine:** Dr. Mahamad Tarik Bakri **Hematology:** Dr Amar Lal
16:30–17:30	Outcome Alignment Standardized suspected-aHUS / TMA trigger criteria. Formalized cross-specialty referral pathways. Practical MDT operating model. EMR-enabled prompts, checklists, or order sets. Pilot implementation in ER / ICU and transplant. Institutional framework that can later be expanded.	All Experts

Day 2 — Sunday 8 November 2026

Opening: ARC — The Full Spectrum of Kidney Care: One Partner, Every Patient, Every Stage *(U.A.E Attendees)*

Featuring

Ultomiris IgAN Launch: UAE

TIME	TOPIC	SPEAKER
09:00–09:30	Registration & Foyer Activation Explore IgAN journey	
09:30–09:40	Ultomiris' 5th Chapter: UAE's 1st Global Approval in IgAN	AZ
09:40–09:50	The Kidney Journey: One Patient, Many Chapters Framing the full CKD spectrum and the strategic rationale for a holistic approach.	Dr. Ayman Al Madani

Part 2: Advances in the Management of IgA Nephropathy

The Disease & The Need — Chairman: Dr. Ayman Al Madani

TIME	TOPIC	SPEAKER
	Moderators: Dr. Chee Kay Cheung, Dr. Hormaz Dastoor	
09:50–10:05	**The Disease:** When IgAN Hits Too Close	Dr. Chee Kay Cheung
10:05–10:20	**The Need:** A Race Against Nephron Loss	Dr. Emad Khater
10:20–10:30	**The Guidance:** KDIGO Guidelines Addressing the Unmet Need	Prof. Jonathan Barratt
10:30–10:40	**The Patient:** A Story of an IgAN Patient	With Dr. Dana Kidder,
10:40–10:50	Session 1 Panel Reflection	Moderators: Dr. Hormaz Dastoor Dr. Chee Kay Cheung

Panelists: *Dr. Shaikha Ali, Prof. Suhail Al Salam, Dr. Muriel Ghosn, Dr. Emad Khater, Prof. Jonathan Barratt, Dr. Dana Kidder.*

10:50–11:00 Coffee Break

Ultomiris IgAN Launch, UAE — Moderators: Prof. Jonathan Barratt, Dr. Hormaz Dastoor

TIME	TOPIC	SPEAKER
11:00–11:15	Why Terminal Complement Inhibition Redefines Precision in IgAN	Dr. Anita Hill
11:15–11:45	From IgAN to ICAN: Advancing the Care for Inflammatory IgAN Patients with Ultomiris Ravulizumab	Prof. Jonathan Barratt
11:45–12:15	Real-World Experience in UAE with Ultomiris: 1st Global	Dr. Dana Kidder, Dr. Hormaz Dastoor Panel Reflection: Prof. Jonathan Barratt, Dr. Anita Hill

Interactive Panel: Hit Hard — When Every Moment Counts — Chairman: Dr. Ahmed Ewaida

12:15–12:30	Real-World Experience on IgAN in the UK: Clinical Case Discussion	Prof. Jonathan Barratt Prof. David Kavanagh
12:30–12:55	Block A (15 min) — Panel: Hit Hard — Which Class to Choose, Facilitated Discussion on Disease-Modifying Agents Block B (10 min) — Patient Profile Gamification *"Build Your Ideal Patient"* Which Patient Would You Deny Access to Complement Inhibitors?	Moderators: Dr. Hormaz Dastoor Prof. Jonathan Barratt
	Panelists: Dr. Amna Al Hadari, Dr. Emad Khater, Dr. Chee Kay Cheung, Dr. Anita Hill, Prof. David Kavanagh.	
12:55–13:00	Closing Remarks & Call to Action (Q&A)	Dr. Ahmed Ewaida, Dr. Hormaz Dastoor (All Speakers)
13:00–13:55	Lunch	

Part 3: Advancing Care for CKD

Chairman: Dr. Ayman Al Madani

TIME	TOPIC	SPEAKER
14:00–14:30	Redefining Renal Resilience with Synergistic Therapeutic Strategies	Dr. Omer Ali
14:30–15:00	Panel Discussion: The MDT Perspective: Managing the Full CKD Spectrum Together Interactive panel • 2–3 live audience polls on real-world CKD cases.	Dr. Omer Ali, Dr. Rana Abou Mrad Dr. Maaz Babiker Dr. Venkat Vellanki Dr. Chee Kay Cheung
15:00–15:05	Closing: "One Partner. Every Patient. Every Stage." Call for collaboration/ summit closing.	Dr. Ayman Al Madani

TODAY'S CHOICES.
TOMORROW'S HEALTH.

ONE PARTNER.
EVERY PATIENT.
EVERY STAGE.

CME

ARC — Advancing Renal Care | Jumeirah Emirates Towers, Dubai | 7–8 November 2026

The information is intended for Healthcare Professionals only.
Prescribing information is available upon request.
Adverse events should be reported to AstraZeneca Pharmacovigilance.
Email: UAE.PV@astrazeneca.com
Phone: 800 AZ (800 292)
Fax: +971 4 509 7555

SPONSORED BY AstraZeneca